Dr. Cosgrove will focus on the strategic execution of the company’s Idiopathic Pulmonary Fibrosis (IPF) clinical development program with its lead compound PLN-74809 a dual selective inhibitor of αvβ6/αvβ1, in clinical development for the treatment of IPF, primary sclerosing cholangitis (PSC), and COVID-19-associated acute respiratory distress syndrome (ARDS).
Dr. Cosgrove will focus on the strategic execution of the company’s Idiopathic Pulmonary Fibrosis (IPF) clinical development program with its lead compound PLN-74809 a dual selective inhibitor of αvβ6/αvβ1, in clinical development for the treatment of IPF, primary sclerosing cholangitis (PSC), and COVID-19-associated acute respiratory distress syndrome (ARDS).